Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 1Castration-resistant Prostate Cancer 1Castration Resistant Metastatic Prostate Cancer 1

Interventions

Specimen Handling 613pembrolizumab 563Magnetic Resonance Spectroscopy 536Carboplatin 425Cisplatin 375Cyclophosphamide 373Biopsy 357Paclitaxel 306Gemcitabine 303Nivolumab 300Radiotherapy 260Bevacizumab 234Dexamethasone 209fludarabine 205Docetaxel 187durvalumab 182atezolizumab 173Oxaliplatin 172venetoclax 168Fluorouracil 166Rituximab 165Pemetrexed 163Capecitabine 158Doxorubicin 157Radiation 155Radiosurgery 148Etoposide 137Leucovorin 133Ipilimumab 133Lenalidomide 131

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × testosterone enanthate × 90 days × Clear all
NCT06594926 2026-04-24

WOMBAT

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Recruiting
69 enrolled
Genitourinary

Prostatic Neoplasms

NCT03522064 2026-04-23

HiTeCH

St Vincent's Hospital, Sydney

Phase 2 Recruiting
30 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT04363164 2026-04-06

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
150 enrolled
Genitourinary

Castration Resistant Metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡